Xenical

orlistat

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

What is Xenical?

Xenical is a medicine containing the active substance orlistat. It is available as turquoise capsules (120 mg).

What is Xenical used for?

Xenical is used together with dieting for the treatment of obese (very overweight) patients with a body mass index (BMI) greater than or equal to 30 kg per square metre, or overweight patients (BMI greater than or equal to 28 kg/m2) who are at risk of illness because of their weight.

The medicine can only be obtained with a prescription.

How is Xenical used?

Xenical is given as one capsule taken with water just before, during, or up to one hour after each main meal. If a meal is missed or contains no fat, Xenical should not be taken. The patient should be on a diet in which about 30% of the calories come from fat, and which is rich in fruit and vegetables. The food in the diet should be spread over three main meals.

Treatment with Xenical should be stopped after 12 weeks if patients have been unable to lose at least 5% of their body weight since the start of treatment.

How does Xenical work?

The active ingredient in Xenical, orlistat, is an anti-obesity medicine, which does not affect appetite. Orlistat blocks gastrointestinal lipases (enzymes that digest fat). When these enzymes are blocked, they cannot digest some fats in the diet, and this allows about 30% of the fat eaten in the meal to pass through the gut undigested. The body cannot use this dietary fat for energy or convert it into fat tissue. This helps weight reduction.

How has Xenical been studied?

The effects of Xenical were first tested in experimental models before being studied in humans.

Xenical has been studied in seven main studies involving over 3,000 overweight or obese patients. The studies lasted from one to two years and compared three different doses of Xenical with placebo (a dummy treatment), in combination with dieting. Neither the patients nor the doctors knew which treatment each patient was taking until the end of the study. An additional longer study in over 3,000 obese patients compared the effects of Xenical and placebo over four years, in combination with diet and exercise. In all studies, the main measure of effectiveness was the change in weight.

What benefit has Xenical shown during the studies?

Xenical was more effective than placebo in producing a reduction in weight. When the results from all seven shorter studies were taken together, patients taking 120 mg Xenical three times a day had an average fall of 6.1 kg in body weight after a year, compared with 2.6 kg in those taking placebo. The proportion of patients losing 10% or more of their body weight was 20% in the patients taking this dose of Xenical and 8% in those taking placebo. At the end of the four-year study, 21% of the patients treated with Xenical had lost more than 10% of their body weight, compared with 10% of the patients who received placebo.

What is the risk associated with Xenical?

The most common side effects with Xenical (seen in more than 1 patient in 10) are influenza (flu), hypoglycaemia (low blood sugar levels), headache, upper respiratory infection (colds), oily spotting from the rectum, abdominal (tummy) pain or discomfort, flatus (gas) with discharge, faecal urgency (urgent need to open the bowels), fatty or oily stools, flatulence (gas), liquid stools, oily evacuation (faeces) and increased defecation. These symptoms generally occur at the beginning of treatment, and go away after some time. For the full description of all side effects reported with Xenical, see the package leaflet.

Xenical should not be used in people who may be hypersensitive (allergic) to orlistat or any of the other ingredients. It should also not be used in people with a long-term malabsorption disease (where nutrients from the food are not easily absorbed during digestion), with cholestasis (a liver disorder) or who are breast-feeding.

Why has Xenical been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Xenical’s benefits are greater than its risks in conjunction with a mildly hypocalorific diet for the treatment of obese patients with a BMI greater or equal to 30 kg/m2, or overweight patients (BMI ≥ 28 kg/m2) with associated risk factors. The Committee recommended that Xenical be given marketing authorisation.

Other information about Xenical

The European Commission granted a marketing authorisation valid throughout the European Union for Xenical to Roche Registration Limited on 29 July 1998. The marketing authorisation was renewed on 29 July 2003 and on 29 July 2008.

Name Language First published Last updated
Xenical : EPAR - Summary for the public BG = bălgarski 2008-11-13  
Xenical : EPAR - Summary for the public ES = español 2008-11-13  
Xenical : EPAR - Summary for the public CS = čeština 2008-11-13  
Xenical : EPAR - Summary for the public DA = dansk 2008-11-13  
Xenical : EPAR - Summary for the public DE = Deutsch 2008-11-13  
Xenical : EPAR - Summary for the public ET = eesti keel 2008-11-13  
Xenical : EPAR - Summary for the public EL = elliniká 2008-11-13  
Xenical : EPAR - Summary for the public EN = English 2008-11-13  
Xenical : EPAR - Summary for the public FR = français 2008-11-13  
Xenical : EPAR - Summary for the public IT = italiano 2008-11-13  
Xenical : EPAR - Summary for the public LV = latviešu valoda 2008-11-13  
Xenical : EPAR - Summary for the public LT = lietuvių kalba 2008-11-13  
Xenical : EPAR - Summary for the public HU = magyar 2008-11-13  
Xenical : EPAR - Summary for the public MT = Malti 2008-11-13  
Xenical : EPAR - Summary for the public NL = Nederlands 2008-11-13  
Xenical : EPAR - Summary for the public PL = polski 2008-11-13  
Xenical : EPAR - Summary for the public PT = português 2008-11-13  
Xenical : EPAR - Summary for the public RO = română 2008-11-13  
Xenical : EPAR - Summary for the public SK = slovenčina 2008-11-13  
Xenical : EPAR - Summary for the public SL = slovenščina 2008-11-13  
Xenical : EPAR - Summary for the public FI = suomi 2008-11-13  
Xenical : EPAR - Summary for the public SV = svenska 2008-11-13  

This EPAR was last updated on 23/09/2016 .

Authorisation details

Product details

Product details for Xenical
NameXenical
Agency product numberEMEA/H/C/000154
Active substance

orlistat

International non-proprietary name (INN) or common name

orlistat

Therapeutic area Obesity
Anatomical therapeutic chemical (ATC) code A08AB01

Publication details

Publication details for Xenical
Marketing-authorisation holder

Roche Registration Ltd.

Revision21
Date of issue of marketing authorisation valid throughout the European Union29/07/1998

Contact address:

Roche Registration Limited
6 Falcon Way
Shire Park
Welwyn Garden City
AL7 1TW
United Kingdom

Product information

Product information

09/08/2016  Xenical -EMEA/H/C/000154 -N/0074

Name Language First published Last updated
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23
Xenical : EPAR - Product Information SV = svenska 2009-05-04 2016-09-23

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19
Xenical : EPAR - All Authorised presentations SV = svenska 2005-12-19 2013-12-19

Pharmacotherapeutic group

Antiobesity preparations, excluding diet products

Therapeutic indication

Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI) greater or equal to 30 kg/m2, or overweight patients (BMI > 28 kg/m2) with associated risk factors.

Treatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at least 5% of the body weight as measured at the start of therapy.

Assessment History